Bortezomib (PS-341)

目录号:S1013 别名: LDP-341, MLM341

Bortezomib (PS-341) Chemical Structure

Molecular Weight(MW): 384.24

Bortezomib (PS-341)是有效的蛋白酶抑制剂,Ki为0.6 nM。它对肿瘤细胞表现出良好的选择性。

规格 价格 库存 购买数量  
RMB 571.94 现货
RMB 2188.92 现货
RMB 5488.32 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户购买Selleck的此次产品后发表的文献148篇:

客户使用该产品的25个实验数据:

  • Immunoblot analysis of cell lysates from the indicated cell lines treated with GNE-6776 (2 μ M for 18 h), either alone or in combination with a UAE1 inhibitor MLN-7243 (5 μ M for 45 min) or the proteasome inhibitor bortezomib (5 μ M for 45 min) as indicated.

    Nature, 2017, 550(7677):534-538. Bortezomib (PS-341) purchased from Selleck.

    Indisulam dependent degradation of RBM39 can be blocked by bortezomib, a proteasome inhibitor. Cells were pretreated with indicated concentrations of bortezomib for 2 hours, followed by 6 hours of treatment with 2 μM indisulam. The effect of bortezomib is attenuated in a bortezomib resistant cell line.

    Science, 2017, eaal3755. Bortezomib (PS-341) purchased from Selleck.

  • Wild-type mice fed as indicated were injected with vehicle (10% DMSO, pH 7.4 PBS) or bortezomib (5 mg/kg bodyweight). Livers were collected 16 hr later for quantitative PCR analysis of indicated genes (n = 4–5). *p < 0.05 bortezomib effect and #p < 0.05 Chol-Diet effect by two-way ANOVA.

    Cell, 2017, 171(5):1094-1109. Bortezomib (PS-341) purchased from Selleck.

    Effect of different proteasome inhibitors on dysferlin expression and on membrane resealing in cultured primary myoblasts. Primary myoblasts from patient 2 harboring a homozygous Arg555Trp DYSF mutation that were treated with the indicated amounts of bortezomib for 24 hours. Western blots of protein extracts were stained with anti-dysferlin antibodies and with anti–a-tubulin antibody as loading control.

    Sci Transl Med 2015 6(250), 250ra112. Bortezomib (PS-341) purchased from Selleck.

  • Pharmacologic inhibition of the proteasome blocks proplatelet formation in murine and human megakaryocytes. Human megakaryocytes were pretreated with vehicle or bortezomib, and megakaryocytes producing proplatelets (PP) were examined. Shown are representative transmission images and representative confocal images with wheat germ agglutinin (WGA; red) and phalloidin (green) staining. Scale bars: 50 um.

    J Clin Invest 2014 124(9), 3757-66. Bortezomib (PS-341) purchased from Selleck.

    Effects of NF-kB inhibition on cell proliferation and apoptosis in Foxp3cKO prostate. A. Top left panels: Representative H&E staining of PIN lesions in ventral prostates of 60-week-old PBS- or bortezomib-treated Foxp3cKO littermates. Scale bar, 50 祄. Right graph: Quantification of Ki67-positive cells identified by IHC analysis (bottom left panels) as a measure of cell proliferation, performed with Scion Image software. Horizontal lines represent the average values. The p value was determined by two-tailed t test. B. Representative western blots showing p65 and nuclear p65 (N-p65) expression in prostates at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. C. Quantification of Bcl2l1 and Traf1/2 mRNA expression as a percentage of Hprt expression measured in microdissected mouse prostate epithelial cells by qPCR at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. Horizontal lines represent the average values. The p values were determined by two-tailed t test. D. Left panels: Representative images of TUNEL assays performed on prostates from PBS- or bortezomib-treated mice at 60 weeks of age. Insets show the apoptotic cells (green) in prostate glands. Scale bar, 100 祄. Right graph: Quantification of apoptotic cells in the ventral and dorsolateral prostates of PBS- or bortezomib-treated mice at 45 and 60 weeks of age. Horizontal lines represent the average values. The p value was determined by two-tailed t test. cKO, PB4-Cre4+Foxp3flox/y; wks, weeks; B/P, ratio of the mean value from bortezomib-treated mice to the mean value in PBS-treated mice. All experiments were repeated two times. Wks, weeks.

    Cancer Res 2015 75(8), 1714-24. Bortezomib (PS-341) purchased from Selleck.

  • Immunofluorescence showing HDAC4 localization in mouse primary osteoblasts treated with vehicle or PTH alone or in the presence of bortezomib. Primary osteoblasts treated with vehicle, PTH, or PTH plus bortezomib for 2 h using anti-HDAC4 and anti-b-actin antibodies.

    J Cell Biol 2014 205(6), 771-80. Bortezomib (PS-341) purchased from Selleck.

    Inhibition of proteasome and lysosome or silencing of VCP and co-factors lead to the accumulation of OP-puro-labeled DRIPs adjacent to or within SGs. HeLa cells were co-treated for 45 min with OP-puro and arsenite (Ars.); where indicated, cells were pretreated with bortezomib (Bort.) overnight and/or ammonium chloride (NH4Cl) for 2 h 15 min. Cells were fixed and labeled with Alexa594-Azide and anti-TIA-1.

    Cell Death Differ 2014 21(12), 1838-51. Bortezomib (PS-341) purchased from Selleck.

  • Immunofluorescence analysis for Ser536 p-NF-κB cellular localization of RS4;11cells treated with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. Cells were treated, collected at 22 h and reacted with an antibody to Ser536 p-NF-κB which was revealed by a Cy3-conjugated secondary antibody. DAPI was used to label nuclei.

    Oncotarget, 2015, 51: S659-S660. Bortezomib (PS-341) purchased from Selleck.

    Control wild-type and Fmn2–/–oocytes observed at different stages of meiotic maturation [prophase I (Pro I), NEBD, 3 hours and 8 hours after NEBD] using anti-Fmn2. wt + Bortezo, wild-type oocytes treated with 0.1μM Bortezomib for 90 minutes before fixation. All oocytes were observed using the same settings and the images treated the same way (three independent experiments). Red arrows indicate cortical labeling. Scale bar: 10μm.

    Development 2011 138, 2903-2908. Bortezomib (PS-341) purchased from Selleck.

  • Cell viability of HCT116 cells treated with a single drug or with the addition of leucovorin.

    Sci Rep, 2017, 7(1):682. Bortezomib (PS-341) purchased from Selleck.

    (B–C) LNCaP (B) and LNCaP-AI (C) cells were transiently transfected with sPLA2-IIa(-800)-Luc (0.5 μg). The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) without or with EGF (100 ng/ml) for 24 h. Luciferase assay was performed according to a standard protocol with Renilla luciferase as an internal control. Data are presented as the mean (±SD) of duplicate values of a representative experiment that was independently repeated for five times.

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

  • LNCaP-AI cells were starved in 1% stripped medium for 24 h. The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) for 24 h. Cell culture medium was collected from each sample and subjected to ELISA for sPLA2-IIa. The condition medium samples were diluted 10 times for ELISA. Average of duplicate samples was converted to nanogram per milliliter against standard curve. The data represent one of five repeated experiments.

     

     

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

    PS-341 impairs FPV replication in A549 cells. (A and B)A549 cells were either pretreated for 1 h with different concentrations of PS-341 or with solvent only or were left untreated. Then, cells were infected with FPV at an MOI of 0.001 (A) or 0.05 (B). After virus inoculation cells were posttreated with different concentrations of PS-341. (A) At 24 h p.i. supernatants were obtained and progeny virus titers were measured by standard plaque assay. (B)Proteasome activity and the ability of PS-341 to inhibit the proteasome was determined 24 h p.i. (C) A549 cells were pretreated with 50 nM PS-341 or solvent or left untreated for 1 h. Afterwards cells were infected with FPV at an MOI of 0.0005. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or solvent or left untreated. After the indicated times p.i.supernatants were obtained and progeny virus titers were determined by standard plaque assay. Arrow bars in all experiments represent standard deviations of three independent experiments.

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • Early steps of viral replication within the first replication cycle are affected. (A) For time-of-addition kinetics analysis, A549 cells were either left untreated or were pretreated for 10 h or 1 h with 50 nM PS-341 before infection and additionally posttreated after infection. Cells were infected with FPV at an MOI of 0.005. After virus inoculation cells were posttreated with 50 nM PS-341. Then the proteasome inhibitor was added after virus inoculation (10 h, 1 h, and 30 min) or it was added at the different times p.i. as indicated (1 h, 2 h, 4 h, 6 h, and 8 h; cells were not pretreated before infection). At 9 h p.i. supernatants were obtained and progeny virus titers were determined by standard plaque assay. Shown is one representative experiment out of three independent experiments. (B) A549 cells were pretreated with 50 nM PS-341 or left untreated for 1 h. Afterwards cells were infected with avian FPV or human PR8 at an MOI of 1. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or left untreated. After the indicated times p.i. cells were lysed and analyzed by Western blotting for accumulation of viral proteins polymerase PB1 and matrix protein M1. Cellular protein ERK2 served as a control to demonstrate equal amounts of protein loading. Shown is one representative blot out of three independent experiments.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    A549 cells were treated with PS-341 at 50 nM for the indicated times or left untreated. Western blotting was performed with total cell lysates, using phospho-specific antibodies against JNK and the transcription factors c-Jun and ATF-2 or loading controls, respectively.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • Western blot of extracts of infected cells treated with different proteasome inhibitors at different concentrations, reacted with the indicated antibodies. p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Time window treatment with proteasome inhibitors. (A) Scheme of the experiment performed with MA104 cells exposed to virus (OSU; MOI, 3) for 1 h and analyzed at the starting point and endpoint of the indicated time window treatments with DMSO, MG132, or bortezomib. (B) Western blot of cellular lysates derived from cells infected for the indicated time periods and treated with the proteasome inhibitors or DMSO. NI, noninfected cells. Blots were reacted with the indicated antibodies; p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Fluorescence analysis of viroplasm formation on NSP5-EGFP cells infected with rotavirus (OSU; MOI, 3) and treated or not treated with MG132 (10 M) or bortezomib (10 M) at different times p.i., as indicated. Cells were analyzed at the starting points (1 h, 3 h, 5 h, 7 h) and endpoints (9 h) of the inhibitor’s window treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Quantification of the accumulation of viroplasms in infected NSP5 -EGFP/MA104 cells. At different times p.i., cells were treated for 4 h with DMSO or the indicated proteasome inhibitor and the number of viroplasms/cell was quantified at the starting (1 h, 3 h, 5 h; white bars) and endpoints (5 h, 7 h, 9 h) of treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • The stable cell line HepAD38 was incubated for 18 h in the presence of the indicated amount of Bortezomib. The medium was removed and replaced by medium containing Bortezomib dissolved in PBS. In case of the control cells the same amount of PBS was added to the medium. 4 h later this procedure was repeated and again 14 h later the supernatant was collected. The amount of viral particles was quantified by real time PCR. HBV-genome quantification was done using COBAS® AmpliPrep/COBAS® TaqMan® HBV test (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s instructions. The assay shows relative values (the value for untreated control cells was arbitrarily set as 1) that are based on three independent experiments. The cell viability was analyzed by MTT assays. For does up to 50 nM no significant effect on cell viability was observed within 18h, for 100 nM the proportion of metabolically active cells was reduced to 83%.

    J Biol Chem 2010 285, 41074-41086. Bortezomib (PS-341) purchased from Selleck.

    HLC-1 cells were treated with IFN-gamma (30 ng/ml) and Bortezomib (0-10 nM) for 3 h. After washing with PBS, the cells were cultured for another 45 h in the fresh medium. After 48 h incubation, PD-L1 expression was analysed by flow cytometry (n =3).

    Int Immunopharmacol, 2018, 54:39-45. Bortezomib (PS-341) purchased from Selleck.

  • Proteasome inhibition effect on biotinylation of MHC-Iα. (a) WB-ra of cellular extracts of HEK293 cells co-transfected with BAP-MHC-Ia and cyt-BirA (control) and, where indicated, with US2 or US11 in the absence (2) or presence of MG132 (MG; 50 μM for 4 h) or Bortezomib(Bort.; 50 μM for 4 h).

    PLoS One 2011 6, e23712. Bortezomib (PS-341) purchased from Selleck.

     

    KKU-M213 was treated with BTZ as indicated. Total cell lysate ( a) and nuclear extract (b) were prepared. Actin and γ -tubulin were loading controls for total and nuclear proteins, respectively.

    2011 Mireia Vila Gasull University of Porto. Bortezomib (PS-341) purchased from Selleck.

  • Mireia Vila Gasull University of Porto. 2011;Mireia Vila Gasull . Bortezomib (PS-341) purchased from Selleck.

产品安全说明书

Proteasome抑制剂选择性比较

生物活性

产品描述 Bortezomib (PS-341)是有效的蛋白酶抑制剂,Ki为0.6 nM。它对肿瘤细胞表现出良好的选择性。
靶点
20S proteasome [1]
(Cell-free assay)
0.6 nM(Ki)
体外研究

Bortezomib,一种硼酸二肽,是一种26S蛋白酶体的高选择性可逆抑制剂,其作用于错误折叠蛋白的降解,并且对细胞周期的调控是必要的。暴露于Bortezomib能够稳定p21,p27,和p53,以及促凋亡Bid和Bax蛋白,微囊蛋白-1,和抑制剂κB-α,这防止了核因子κB诱导的细胞存活途径的激活。Bortezomib也会促进促凋亡c-Jun-NH2末端激酶,以及内质网应激反应的激活。这些细胞蛋白水平的改变导致对增殖,迁移的抑制,和癌细胞凋亡的促进。[2] Bortezomib能够渗透到细胞,并抑制蛋白酶体介导的细胞内长寿蛋白水解,抑制50%蛋白质水解的浓度为∼0.1 μM。Bortezomib对衍生自美国国家癌症研究所(NCI)多重人类肿瘤的一组60个癌细胞系的IC50值为7 nM。PC-3细胞用Bortezomib (100 nM)处理8小时导致细胞积聚在G2-M期,相应的G1期细胞数量减少。Bortezomib在24和48小时杀死PC-3细胞,IC50分别为100和20 nM。Bortezomib治疗16-24小时后诱导细胞核缩合。Bortezomib在低至100 nM浓度下以时间依赖的方式导致PARP裂解,在处理24小时后产生效果。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 MXLDfZRwfG:6aXOgRZN{[Xl? MlfWOVAh|ryP MX60PEBp NUj5[nM1TE2VTx?= NWD4U5k6U2mubIOgZ4VtdHNiYomgcY9z\SC2aHHuJFk6LQ>? MkW3NVA1QTl4NEO=
OVCA 429 MmKySpVv[3Srb36gRZN{[Xl? MVuzNFAhdk1? NFThSmU1QCCq NUDabmI1TE2VTx?= NHX4XJhFcXO{dYD0d{BqdnSjY4SgcZVtfGmlZXzseYxieiC2dX3vdkB{eGincn;p[JM> MWSxNFk6QTd4Nh?=
RPMI8226 NX;jZohCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\vSmEyODBibl2= NYnGS|N5PDhiaB?= MVXEUXNQ M3TkWWlEPTB;M{Cgcm0> Mn6xNVE{ODZ2OEm=
Dox40 M4PnXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYOxNFAhdk1? NXnSOmhuPDhiaB?= MX3EUXNQ NF23SIhKSzVyPUSwJI5O MUCxNVMxPjR6OR?=
MR20 M{G5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPLUo0yODBibl2= NF3n[4U1QCCq MXTEUXNQ NU[4bpVRUUN3ME2yNEBvVQ>? NWjuTlgyOTF|ME[0PFk>
LR5 Mo\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojxNVAxKG6P MV60PEBp MlrHSG1UVw>? M1rENWlEPTB;MkCgcm0> MWixNVMxPjR6OR?=
U266 NFflRXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2j0TlExOCCwTR?= M1XEWlQ5KGh? MlPkSG1UVw>? M1X2SWlEPTB;MzDuUS=> NIC3UZAyOTNyNkS4PS=>
IM-9 M4fEWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLhXnYyODBibl2= M1jVWVQ5KGh? MnfXSG1UVw>? NXLwSldzUUN3ME22JI5O M3H3b|EyOzB4NEi5
Hs Sultan NVzhTpJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fwelExOCCwTR?= MnT4OFghcA>? M3rBXWROW09? M1HZNGlEPTB;MkCgcm0> NGXhdmEyOTNyNkS4PS=>
PAM-LY2 NUjtZWFVTnWwY4Tpc44hSXO|YYm= M1vwTlExOCCwTR?= NXPncVlNOTJiaB?= NHjHZVhFVVOR M2LqSGlvcGmkaYTzJG5HNc78QjDhZ5RqfmG2aX;u M1XMZVEyOzVyOUGz
PAM 212 NXvGdIdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfaNHJUOTByIH7N MYi3NkBp MVnEUXNQ MUXJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? MkfZNVE{PTB7MUO=
PAM-LY2 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NImzSZoyODBibl2= NFWzXW84OiCq MmPRSG1UVw>? NXjaPWhbUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= MmTvNVE{PTB7MUO=
B4B8 MlnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVOxNFAhdk1? MXy3NkBp M4e3e2ROW09? M3vOfmlvcGmkaYTzJINmdGxidnnhZoltcXS7 MUCxNVM2ODlzMx?=
B7E3 NGDrXJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHNc2EyODBibl2= M125fVczKGh? NXjrcpp[TE2VTx?= MlSyTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? M3nKZlEyOzVyOUGz
UM-SCC-9 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXFNVAxKG6P MYG3NkBp M1HFNGROW09? MoDrTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? NF3hfnYyOTN3MEmxNy=>
UM-SCC-11B NVTKOnBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDRNVAxKG6P MY[3NkBp MWHEUXNQ M2eyN2lvcGmkaYTzJINmdGxidnnhZoltcXS7 NHr2UXYyOTN3MEmxNy=>
H460 MXjGeY5kfGmxbjDBd5NigQ>? MUKxNEDPxE1? NFfLSo4zPCCq MUjEUXNQ MVfJcoR2[2W|IFLjcE0zKHCqb4PwbI9zgWyjdHnvckBidmRiY3zlZZZi\2ViY3;ydoVt[XSnZDD3bZRpKEd{LV2gdIhie2ViYYLy[ZN1 NYrEeI06OTJ2OUKxNVc>
U266 Mn2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYO1NFAhdmdxbXy= MkPTOFghcA>? MUfEUXNQ M{TtZmlvcGmkaYTzJINmdGxiZ4Lve5Rp MmPsNVI3OzF4MUm=
ARH77 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\oOVVoPTByIH7nM41t MknVOFghcA>? MW\EUXNQ M3jY[WlvcGmkaYTzJINmdGxiZ4Lve5Rp MXGxNlY{OTZzOR?=
WAD-1 NGnJXIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrCeGY2ODBibnevcYw> NHHVfoY1QCCq MYjEUXNQ MUHJcohq[mm2czDj[YxtKGe{b4f0bC=> M2XoelEzPjNzNkG5
U266/LR7 NU[4PZh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDhOVAxKG6pL33s NXjFW2FsPDhiaB?= MX7EUXNQ M2jNd2lvcGmkaYTzJINmdGxiZ4Lve5Rp Ml;ZNVI3OzF4MUm=
U266/dox4 NFTxeY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXqOo82ODBibnevcYw> M4nkRlQ5KGh? NGDtVXhFVVOR MUjJcohq[mm2czDj[YxtKGe{b4f0bC=> MV[xNlY{OTZzOR?=
RPMI8226/LR5 NH\wSFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzYT2w1PTByIH7nM41t M1vWO|Q5KGh? M1LnWmROW09? M3X5cmlvcGmkaYTzJINmdGxiZ4Lve5Rp MoDoNVI3OzF4MUm=
H460 NEPtVm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{i1[|ExKM7:TR?= NFfuVIU4OiCq NEPrVm5FVVOR NWHUN3hFUUN3ME2xNFAhdk1? M17zNVEzPjNzNkKw
H358 MmLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\WSFExKM7:TR?= NY\PS4liPzJiaB?= Ml7xSG1UVw>? NV;ucHRiUUN3ME23NEBvVQ>? NXfDTplSOTJ4M{G2NlA>
H322 NH6wfmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYqxNEDPxE1? NWDQNnhZPzJiaB?= NWLVU2pqTE2VTx?= MomyTWM2OD14MkCgcm0> NGfpflIyOjZ|MU[yNC=>
H460 M4WzdmZ2dmO2aX;uJGF{e2G7 NXjZVnZzOTByIH7N Mni3NlQhcA>? M3WzfmROW09? NHXEOmVKdmS3Y3XzJGczNU1vcHjhd4Uh[XK{ZYP0JIFv\CC2dXL1cIlvKGG|c3XtZox6NWSrc3Hzd4Vu[my7 NWT5ZmhDOTJ4M{G2NlA>
LNCap-Pro5 NWrkbnRTTnWwY4Tpc44hSXO|YYm= NXPCenFROSEQvF2= MkDoOEBp NGnybJZFVVOR M2LXRXN1[WKrbHn6[ZMheDV| NXLwd4E3OTR4MUK1N|I>
T29 NF;NRWJCeG:ydH;zbZMhSXO|YYm= M1HJcFUxKG6P M2\1b|Q5KGhi NXjz[|VqTE2VTx?= M1nmZmlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MV6xOlc4QDF5OR?=
T29Kt1 MX3BdI9xfG:|aYOgRZN{[Xl? MmXROVAhdk1? MVy0PEBpKA>? M4XYRmROW09? MUDJcoR2[2W|IHPlcIwh[XCxcITvd4l{ MVyxOlc4QDF5OR?=
HCT116 NYTpN|ZxSXCxcITvd4l{KEG|c3H5 NXXMXIN{PTBibl2= MU[0PEBpKA>? MX\EUXNQ NVrHUYloUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MYCxOlc4QDF5OR?=
HKe-3 M2K3UWFxd3C2b4Ppd{BCe3OjeR?= Mmf2OVAhdk1? NHjtVII1QCCqIB?= M3TJ[WROW09? NYmwdWlvUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NWDYfXRFOTZ5N{ixO|k>
NB-1691 M{\Re2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWqxJO69VQ>? NXXsbmp{PzJiaB?= NEXZXXhKdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hfG9iNTW= MVWxO|Y5QTZ6NB?=
CHLA-255 NGrNbpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3z0NFEh|ryP M1fYWlczKGh? NFra[YFKdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hfG9iMjW= NGn1W4UyPzZ6OU[4OC=>
SK-N-AS MmHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHWzWZoyKM7:TR?= MX[3NkBp MlL3TY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJJRwKDFyJR?= NWK3RpVxOTd4OEm2PFQ>
NB-1691 M3zDXmZ2dmO2aX;uJGF{e2G7 NFq4enEyOCCwTR?= NWDHO3VnOjRiaB?= NYWxS|h2W2mpbnnmbYNidnSueTDy[YR2[2W|IHPlcIx{KGmwIITo[UBIOC:JMTDwbIF{\Q>? NXfZZos1OTd4OEm2PFQ>
CHLA-255 NWr4cXJjTnWwY4Tpc44hSXO|YYm= MUKxNEBvVQ>? MoPLNlQhcA>? M1e5dG1w\GW|dHz5JJJm\HWlZYOgZ4VtdHNiaX6geIhmKEdyL1exJJBp[XOn MVixO|Y5QTZ6NB?=
RPMI 8226 MnvPSpVv[3Srb36gRZN{[Xl? MXmyNEBvVQ>? MYm4JIg> M2frWXNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 MlzxNVk1OzZyNUC=
MM.1S NHjz[mpHfW6ldHnvckBCe3OjeR?= MX[yNEBvVQ>? MX24JIg> M1KzbXNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 MnLtNVk1OzZyNUC=
U266 M1LNfmZ2dmO2aX;uJGF{e2G7 NEO0WFUzOCCwTR?= MWe4JIg> MoLJV4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk> NFuzOnkyQTR|NkC1NC=>
OPM1 NWG5WVVmTnWwY4Tpc44hSXO|YYm= M{PBNFIxKG6P M4H4W|ghcA>? NYH2fWp{W2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl? MX2xPVQ{PjB3MB?=
INA6 MYPGeY5kfGmxbjDBd5NigQ>? MX6yNEBvVQ>? NGmxTVQ5KGh? NXSwO4JsW2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl? NU[5RllqOTl2M{[wOVA>
OPM2 MVvGeY5kfGmxbjDBd5NigQ>? NXKyWm5qOjBibl2= M3P5fVghcA>? NWPDWGdJW2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl? NF3SWmMyQTR|NkC1NC=>
RPMI 8226 MXPGeY5kfGmxbjDBd5NigQ>? NYLsc2pXOjBibl2= NFW4WHE5KGh? MoqyTY5lfWOnczDEUmEhe3mwdHjld4l{ NWCzboU5OTl2M{[wOVA>
BaF/3 MnXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGj0XHkyODBibl2= NIX0Z5I1QCCq NYXPd25bUUN3ME22MlIhdk1? MnrMNlA{ODV4OUK=
BaF/3-p210 NGm1[4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;CTWU2OTByIH7N MkDEOFghcA>? NF\VRlBKSzVyPUSuO{BvVQ>? MoW4NlA{ODV4OUK=
TCC-S MkPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrUOmtnOTByIH7N NHz1dnk1QCCq NV7JOGk6UUN3ME2yMlghdk1? NWPFS5dTOjB|MEW2PVI>
BaF/3 MWLGeY5kfGmxbjDBd5NigQ>? MlzxOkBvVQ>? MYO0PEBp NFe3bGNKdmS3Y3XzJIEh\3KnYYSgS|Eh[2WubD3jfYNt\SCjcoLld5Q> MY[yNFMxPTZ7Mh?=
BaF/3-p210 M4\udGZ2dmO2aX;uJGF{e2G7 MomzOkBvVQ>? MlnPOFghcA>? MkfVTY5lfWOnczDhJJNtcWeqdDDHNUBk\WyuLXP5Z4xmKGG{cnXzeC=> MXSyNFMxPTZ7Mh?=
BaF/3-p210 MlzDSpVv[3Srb36gRZN{[Xl? MXm2JI5O NFzrNogzPCCq M1vrb3Jm\HWlZYOgeIhmKHCqb4PwbI9zgWyjdHnvckBidmRidHjlJIFkfGm4aYT5JI9nKFKk MX2yNFMxPTZ7Mh?=
Raji NVTrSIJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXOyWXNKOSEQvF2= NGXQXnAzPCCq MnGwVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi NF;TUoMzOTF5MEm4PC=>
LCL-1 NGD0ZXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVy0eog1OSEQvF2= Moi1NlQhcA>? NW\mOpU{WmWmdXPld{Bk\WyuII\pZYJqdGm2edMg MXqyNVE4ODl6OB?=
LCL-2 NEnrVJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTmWHYyKM7:TR?= MmD4NlQhcA>? MVnS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? M17yblIyOTdyOUi4
BJAB NFfOc|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWexJO69VQ>? MUGyOEBp NGTwWnhT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= NEPGN|AzOTF5MEm4PC=>
SNT-13 M4DD[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXCVIEyKM7:TR?= MUeyOEBp MUjS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? MV[yNVE4ODl6OB?=
SNT-16 M{D6PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW[xJO69VQ>? NYD0fppmOjRiaB?= NXTVZYR3WmWmdXPld{Bk\WyuII\pZYJqdGm2edMg MU[yNVE4ODl6OB?=
Jurkat M3\IZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHXUWIyKM7:TR?= NFf1Z4szPCCq M3vsdnJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= MlHWNlEyPzB7OEi=
KAI-3 M3P2NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXKxJO69VQ>? NI\Ed2UzPCCq MlfxVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi NE\iOoMzOTF5MEm4PC=>
SNK-6 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTqdotDOSEQvF2= NFjpZ3czPCCq NETUeVBT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= MXWyNVE4ODl6OB?=
KHYG-1 M2jCfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHJ[Jl[OSEQvF2= NW\aW2RCOjRiaB?= NXjUflhEWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg M3zwTlIyOTdyOUi4
SNT-16 M2KzUWFxd3C2b4Ppd{BCe3OjeR?= MmPFNUDPxE1? M{T2cFYhcA>? M2iwSGlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? Ml3pNlEyPzB7OEi=
Jurkat NGrySIpCeG:ydH;zbZMhSXO|YYm= M1LYWlEh|ryP MY[2JIg> M1T6XWlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NED2bZIzOTF5MEm4PC=>
KAI-3 M3\XdWFxd3C2b4Ppd{BCe3OjeR?= M1zhXlEh|ryP M{nWc|YhcA>? MXPJcoR2[2W|IHPlcIwh[XCxcITvd4l{ M2XsXlIyOTdyOUi4
KHYG-1 MorFRZBweHSxc3nzJGF{e2G7 NEK3dFEyKM7:TR?= M4LWbVYhcA>? M3LmVGlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M1m3VlIyOTdyOUi4
SNT-13 NVK5VY9ESW62aY\pdoFtKEG|c3H5 M1O1bFEh|ryP MoK3NlQhcA>? MX7JcoR2[2W|IHz5eIlkKGmwZnXjeIlwdiCxZjDFRnY> M33nblIyOTdyOUi4
SNT-16 MlPURY51cX[rcnHsJGF{e2G7 MYGxJO69VQ>? MmDsNlQhcA>? MUDJcoR2[2W|IHz5eIlkKGmwZnXjeIlwdiCxZjDFRnY> NVX1NVdIOjFzN{C5PFg>
KAI-3 NFvsUIxCdnSrdnnyZYwhSXO|YYm= M3qxPFEh|ryP NXn4RpJpOjRiaB?= NE\ZWnZKdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ? Mki3NlEyPzB7OEi=
SNK-6 MVrBcpRqfmm{YXygRZN{[Xl? NW\BUm5POSEQvF2= NXHsSZhwOjRiaB?= MUTJcoR2[2W|IHz5eIlkKGmwZnXjeIlwdiCxZjDFRnY> MnrNNlEyPzB7OEi=
RAW 264.7 NEnUc4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvpZolwOTByIH7N NFPaUWM1QCCq M4[4dHJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= M33XflIzPDJ5MUW0
A375 M3;obGFxd3C2b4Ppd{BCe3OjeR?= NXPNNG9JOTBibl2= M4\DZVI1KGh? M1e2[mlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MkLZNlMxPzlyOEO=
BLM NGPXV3NCeG:ydH;zbZMhSXO|YYm= Mn21NVAhdk1? MXiyOEBp NF3iNVBKdmS3Y3XzJINmdGxiYYDvdJRwe2m| M{XKflI{ODd7MEiz
A375 NWOzeGp2SXW2b4DoZYd6KEG|c3H5 M3jkUFExKG6P NVXt[mk{OTJiaB?= MVXJcoR2[2W|IH\vdo1ifGmxbjDv[kBifXSxcHjh[49{d22ncx?= MVOyN|A4QTB6Mx?=
BLM MkXJRZV1d3CqYXf5JGF{e2G7 MXuxNEBvVQ>? MorHNVIhcA>? MlW3TY5lfWOnczDmc5Ju[XSrb36gc4Yh[XW2b4DoZYdwe2:vZYO= NHTNc4MzOzB5OUC4Ny=>
H1299 NXnodmZWSXCxcITvd4l{KEG|c3H5 NEO1bXM5OCCwTR?= MlvtNlQhcA>? M1qzfWROW09? MXrT[Y5{cXSrenXzJG5US0yFIHPlcIx{KHSxIF3TR{1l\XKrdnXkJIlEQS2rbnT1Z4VlKGGyb4D0c5Nqew>? NYX5UZBXOjV|MkO2PVM>
Hut-78 M3uxOGZ2dmO2aX;uJGF{e2G7 MWqxNFAhdk1? M2rlcFI1KGh? M4XhTWROW09? NGPR[3RFd3ewcnXneYxifGW|IGTHSk3PujFiYX7kJGlNNTFyIHX4dJJme3Orb36= MV6yOVY5OTN|NR?=
H9 MnHrSpVv[3Srb36gRZN{[Xl? NVy0RYhwOTByIH7N NUK1T4puOjRiaB?= MXHEUXNQ M{DCcGRwf26{ZXf1cIF1\XNiVFfGMe6zOSCjbnSgTWwuOTFiZYjwdoV{e2mxbh?= MUOyOVY5OTN|NR?=
HH NHfWVFJHfW6ldHnvckBCe3OjeR?= M3XoNFExOCCwTR?= NWrC[Jc{OjRiaB?= NFi0eGpFVVOR M17QNIRwf26{ZXf1cIF1\XNiVFfGMe6zOSCjbnSgTWwuOTJiZYjwdoV{e2mxbh?= Mn7tNlU3QDF|M{W=
Hut-78 NGHDR2VOcWe{YYTpc44hSXO|YYm= M4T2VFExOCCwTR?= NU\XfFlUOjRiaB?= NX\PVXJZTE2VTx?= MnTxVoVlfWOnczDj[YxtKG2rZ4LheIlwdiCkeTC4NQKBmzlyJR?= NFHxOHMzPTZ6MUOzOS=>
HH MnnqUYloemG2aX;uJGF{e2G7 M4TFUVExOCCwTR?= NXHlOlB4OjRiaB?= M1LFTmROW09? NV3iU4hLWmWmdXPld{Bk\WyuIH3p[5JifGmxbjDifUA5OOLCk{mxKS=> M{KxSFI2PjhzM{O1
U937 NIe3elJHfW6ldHnvckBCe3OjeR?= NFvUVXMyODBibl2= NYXXRYQ5PiCq MnnKTY5lfWOnczDJUE05KGW6cILld5Nqd25iaX6gUHBUNXO2aX31cIF1\WRiVUmzO{Bu[WO{b4DoZYdmew>? NFrCUIEzPTd7MUS3Oy=>
human PBMC MlrOSpVv[3Srb36gRZN{[Xl? MmfsNVAxKG6P MnLyNlQhcA>? NEnPVJRKdmS3Y3XzJGlNNThicnXs[YF{\Q>? NWL2V2RIOjV5OUG0O|c>
ES6 M3HSdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnXPZFKSzVyPUCuNFAzOSCwTR?= M2LWOXNCVkeHUh?=
SK-UT-1 M33MT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHsXZNKSzVyPUCuNVY{KG6P MWHTRW5ITVJ?
SH-4 NG[wOGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfwSZpzUUN3ME2wMlE4OyCwTR?= MlHpV2FPT0WU
TE-9 NYLwXVRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;icGlEPTB;MD6xPFIhdk1? MknkV2FPT0WU
A253 NVfSZVJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPWTWM2OD1yLkKwPEBvVQ>? MoizV2FPT0WU
no-10 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LGO2lEPTB;MD6yNUBvVQ>? M3jrUHNCVkeHUh?=
MMAC-SF MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTBwMkG2JI5O NULSdXpOW0GQR1XS
A101D M376Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3PWYVjUUN3ME2wMlIzPSCwTR?= MYjTRW5ITVJ?
NTERA-S-cl-D1 MnXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jtS2lEPTB;MD6yOFMhdk1? NFWwdnNUSU6JRWK=
8-MG-BA MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrQZ5FKSzVyPUCuNlUhdk1? NWTSS2p[W0GQR1XS
KNS-42 NF\EOoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnvfJpKSzVyPUCuNlU5KG6P NYjFWGI1W0GQR1XS
LXF-289 NIrDeGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnDe49KSzVyPUCuNlY6KG6P MV;TRW5ITVJ?
OVCAR-4 M{P0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTkVllJUUN3ME2wMlI5QSCwTR?= M2mzSnNCVkeHUh?=
LOUCY NVOwWFNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPtXlhKSzVyPUCuNlk{KG6P MXzTRW5ITVJ?
BB65-RCC NUXWd2xuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTBwM{C0JI5O NHHPV3RUSU6JRWK=
D-542MG MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrxTWM2OD1yLkOyPUBvVQ>? M1r3UXNCVkeHUh?=
ONS-76 M{e3cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7qVo5KSzVyPUCuN|Mhdk1? MlHvV2FPT0WU
BB30-HNC NY\iO3NtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTBwM{O1JI5O NGfVRmRUSU6JRWK=
KS-1 NVHseJNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\o[WxKSzVyPUCuN|Qhdk1? MUfTRW5ITVJ?
A388 NVyzW2NrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\2N3JRUUN3ME2wMlM2PiCwTR?= NVW3Vm42W0GQR1XS
ES8 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTBwNDDuUS=> MVzTRW5ITVJ?
MZ2-MEL M4nUXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY[w[ldCUUN3ME2wMlQxPyCwTR?= NYLhXIllW0GQR1XS
HCC2998 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7qcVBKSzVyPUCuOFEzKG6P NHzMOZJUSU6JRWK=
D-247MG MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLVU2dKSzVyPUCuOFE{KG6P M{LGWHNCVkeHUh?=
ACN M2LHWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrMTmdKSzVyPUCuOFE4KG6P M{\3Z3NCVkeHUh?=
LB2518-MEL NWLHS|lxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\tWHFWUUN3ME2wMlQzPSCwTR?= MlLqV2FPT0WU
ES1 M1rqU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37hRmlEPTB;MD60N{BvVQ>? NF\jN2dUSU6JRWK=
HCE-T NH22UWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTBwNEO5JI5O M{XMS3NCVkeHUh?=
OS-RC-2 NVfCU2I1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTBwNESgcm0> NYTMfXdjW0GQR1XS
MFH-ino NIXkTm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTBwNESzJI5O NUj3WGdNW0GQR1XS
OCUB-M Mm\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTBwNES3JI5O MlrOV2FPT0WU
CP66-MEL NILZWmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjKNpBYUUN3ME2wMlQ4OyCwTR?= M3jUWHNCVkeHUh?=
LB771-HNC MoiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjnOpNKSzVyPUCuOFc1KG6P MnL3V2FPT0WU
DSH1 NV3PSYpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDkfGtpUUN3ME2wMlQ5KG6P NHzxOlRUSU6JRWK=
HUTU-80 NFHNWpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlroTWM2OD1yLkWzN{BvVQ>? M{jxZ3NCVkeHUh?=
CESS M2q4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7jXotKSzVyPUCuOVM5KG6P NF3YN5JUSU6JRWK=
NCI-H747 NXfrc|dDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3P1SGlEPTB;MD61N|khdk1? M1zWOnNCVkeHUh?=
HT-144 NX[2XJM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTBwNUe2JI5O MU\TRW5ITVJ?
COLO-829 NUHNPJM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;Vb2dKSzVyPUCuOlE1KG6P MlPYV2FPT0WU
A4-Fuk NGHzVpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTBwNkKzJI5O M1vnXXNCVkeHUh?=
GI-ME-N MojhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\LfWlEPTB;MD62N|Qhdk1? M2DjUnNCVkeHUh?=
LB831-BLC MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY[5VFJPUUN3ME2wMlY1OSCwTR?= MV3TRW5ITVJ?
HOP-62 NE\jToJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LrZWlEPTB;MD62OFchdk1? NVSxNlFFW0GQR1XS
BB49-HNC NWLFW45kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPONo5TUUN3ME2wMlY2OiCwTR?= M1ridnNCVkeHUh?=
D-336MG MnnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jnVGlEPTB;MD62OVchdk1? NWfRXXV1W0GQR1XS
TK10 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LWcmlEPTB;MD62O|khdk1? Mo\MV2FPT0WU
Ramos-2G6-4C10 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLHTWM2OD1yLk[5N{BvVQ>? NWricHlQW0GQR1XS
LB373-MEL-D M37W[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;0[4NKSzVyPUCuO{BvVQ>? MorsV2FPT0WU
SF126 M4TkcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTDTWM2OD1yLkewNUBvVQ>? M1PUdXNCVkeHUh?=
UACC-257 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;LTWM2OD1yLkexJI5O NGH5dJRUSU6JRWK=
KINGS-1 M1XJUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojuTWM2OD1yLkeyNkBvVQ>? NFvOXYpUSU6JRWK=
LS-513 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDETWM2OD1yLkezPUBvVQ>? MVrTRW5ITVJ?
GI-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXOOXlKSzVyPUCuO|Y1KG6P NFjJfGZUSU6JRWK=
ES7 M2DHXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlT1TWM2OD1yLke2OkBvVQ>? NILt[nJUSU6JRWK=
LB2241-RCC NWT1XmNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHnZ3U5UUN3ME2wMlgxPCCwTR?= NXHHNodyW0GQR1XS
D-263MG MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTBwOEC3JI5O MkHwV2FPT0WU
SW684 M2nwV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXW5Z2RXUUN3ME2wMlgzOSCwTR?= MYHTRW5ITVJ?
ML-2 NVHkOVhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjXTYF[UUN3ME2wMlgzOSCwTR?= MmqwV2FPT0WU
SK-LMS-1 M4Dre2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nMS2lEPTB;MD64OVQhdk1? NWnNdGF1W0GQR1XS
TE-5 MmPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1n4dGlEPTB;MD64OlUhdk1? MWLTRW5ITVJ?
QIMR-WIL MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTZV2d3UUN3ME2wMlg5QSCwTR?= M2DPVnNCVkeHUh?=
NCI-H1355 NUnrO4ZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnWenZKSzVyPUCuPFk2KG6P NGm1SmhUSU6JRWK=
SNB75 MnHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;5SmlKSzVyPUCuPVEzKG6P MVfTRW5ITVJ?
RXF393 NWXo[GFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTBwOUG0JI5O MnzYV2FPT0WU
IST-MEL1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1mwdmlEPTB;MD65NVchdk1? NFi1e3BUSU6JRWK=
SF268 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmSxTWM2OD1yLkmyN{BvVQ>? NXzMWYJnW0GQR1XS
KALS-1 MkLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3wNG9YUUN3ME2wMlkzPSCwTR?= MX\TRW5ITVJ?
HC-1 M4TPPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLJTWM2OD1yLkm3OUBvVQ>? M1XYc3NCVkeHUh?=
SW872 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLyN5BKSzVyPUCuPVk3KG6P Mk\zV2FPT0WU
PSN1 M4Lv[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTFwMEGgcm0> NHfFNW9USU6JRWK=
TE-1 MoH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;mRXpbUUN3ME2xMlA{KG6P NVnNU4k6W0GQR1XS
TE-10 M3ziTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTFwMEOgcm0> MXfTRW5ITVJ?
RKO NXzw[ZNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M173UmlEPTB;MT6wOkBvVQ>? MXPTRW5ITVJ?
LC-2-ad NXXFclA{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmi2TWM2OD1zLkC4JI5O NHq4cnRUSU6JRWK=
SK-MM-2 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnHVZl4UUN3ME2xMlA6KG6P MXTTRW5ITVJ?
VA-ES-BJ MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nF[GlEPTB;MT6wPUBvVQ>? NHHufpdUSU6JRWK=
MZ7-mel MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;ZfmlEPTB;MT6wPUBvVQ>? M3LrO3NCVkeHUh?=
D-392MG NX3kR5k3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXJNlFoUUN3ME2xMlEhdk1? MlrHV2FPT0WU
CCRF-CEM MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfTTWM2OD1zLkGzJI5O MmL0V2FPT0WU
EM-2 NHHIOoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTFwMU[gcm0> NX\uT21jW0GQR1XS
HAL-01 Mlr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTFwMUigcm0> NYDyUnRwW0GQR1XS
TE-8 NVjDVplvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTFwMUmgcm0> MVPTRW5ITVJ?
NCI-H1882 M1q5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnNfIdKSzVyPUGuNkBvVQ>? MUnTRW5ITVJ?
Daudi M335dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTFwMkKgcm0> NEX6RXdUSU6JRWK=
BL-41 NVSzVWY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlv2TWM2OD1zLkK1JI5O NEXMU4FUSU6JRWK=
SR M{\FZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HSdmlEPTB;MT6yOUBvVQ>? MoXNV2FPT0WU
KM12 M2HWVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXoPYlQUUN3ME2xMlI4KG6P MVjTRW5ITVJ?
K5 M1LufWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGi3TW5KSzVyPUGuNlghdk1? M2TNeXNCVkeHUh?=
A3-KAW NHe3XWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mor2TWM2OD1zLkK4JI5O MkTkV2FPT0WU
CMK Ml\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\he4JKSzVyPUGuNlkhdk1? NWnTOno4W0GQR1XS
Calu-6 MlzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTFwMkmgcm0> NXf2NXk4W0GQR1XS
IST-SL2 MlrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojUTWM2OD1zLkOxJI5O NUC5cW9GW0GQR1XS
OPM-2 M3LJdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrsZ3h1UUN3ME2xMlM{KG6P MYDTRW5ITVJ?
DU-4475 NXXSSmVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zCTWlEPTB;MT6zOkBvVQ>? MWjTRW5ITVJ?
ECC12 NHr3Z3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTBb4dKSzVyPUGuN|chdk1? M2TjNXNCVkeHUh?=
L-540 NHnmbmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHRTWM2OD1zLkO3JI5O MVvTRW5ITVJ?
CAS-1 Ml\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\0TWM2OD1zLkO3JI5O NUDwN4RXW0GQR1XS
PF-382 M3\mV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HFbWlEPTB;MT60O{BvVQ>? MULTRW5ITVJ?
LS-411N NHe4V5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnySJJKSzVyPUGuOVMhdk1? MVPTRW5ITVJ?
NCI-H69 NFKzeJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfydIU5UUN3ME2xMlU1KG6P MkX1V2FPT0WU
NB12 M4H6Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTFwNU[gcm0> MWPTRW5ITVJ?
HEL Mon0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nEfGlEPTB;MT62NUBvVQ>? NX\2N2JQW0GQR1XS
GCIY MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjueoJKSzVyPUGuOlIhdk1? M3vidHNCVkeHUh?=
EHEB M2rOemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDYTWM2OD1zLk[3JI5O MYrTRW5ITVJ?
TGBC1TKB MoHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWH5PHI2UUN3ME2xMlcyKG6P NX;IW5ZVW0GQR1XS
KURAMOCHI MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7YO2dCUUN3ME2xMlczKG6P MofXV2FPT0WU
U-266 Ml35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrGSXhKSzVyPUGuO|Yhdk1? M3rvOXNCVkeHUh?=
LC4-1 NVX1TVJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjLUIRKSzVyPUGuO|khdk1? M4PWOHNCVkeHUh?=
NCI-H2126 M3HWOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfqTWM2OD1zLkigcm0> MoDOV2FPT0WU
NCI-H1092 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEf3VlJKSzVyPUGuPEBvVQ>? MUDTRW5ITVJ?
GB-1 M2HwPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW[1UZlZUUN3ME2xMlgyKG6P MV;TRW5ITVJ?
MV-4-11 NHLZcopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\FTWM2OD1zLkiyJI5O MXPTRW5ITVJ?
Becker MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NID1NlNKSzVyPUGuPFMhdk1? NH36XmNUSU6JRWK=
MPP-89 MmfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTFwOEmgcm0> M2TCNHNCVkeHUh?=
BE-13 MmSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIe4doRKSzVyPUGuPVMhdk1? NFHyU4hUSU6JRWK=
697 MnjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jRemlEPTB;MT65PUBvVQ>? NV\ud5BYW0GQR1XS
NKM-1 M2XFeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVuzS5N7UUN3ME2yJI5O MWjTRW5ITVJ?
NB13 Mlu0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHQUXlKSzVyPUKgcm0> M{LHNXNCVkeHUh?=
LS-123 NX:2NHV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTJwMEKgcm0> NYjzdWNlW0GQR1XS
NB17 MoTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojSTWM2OD1{LkC0JI5O NWHlW4F[W0GQR1XS
LAN-6 M4LBRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLYTWM2OD1{LkC1JI5O NFjTW2pUSU6JRWK=
EW-24 M3;zeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPMfWlKSzVyPUKuNFghdk1? NYjF[W1FW0GQR1XS
NOS-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3sR2E1UUN3ME2yMlEyKG6P M3zvcHNCVkeHUh?=
BL-70 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXtVFdkUUN3ME2yMlEzKG6P M4jaZXNCVkeHUh?=
GT3TKB MknsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTJwMUKgcm0> MXHTRW5ITVJ?
HH M1fYcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnrTWM2OD1{LkGzJI5O MU\TRW5ITVJ?
KE-37 NHzWW4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rzUmlEPTB;Mj6xN{BvVQ>? M4XITXNCVkeHUh?=
MOLT-4 NVfVNJI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfZTWM2OD1{LkGzJI5O NH;nPFVUSU6JRWK=
EKVX Mn:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTJwMUSgcm0> NIPCO4dUSU6JRWK=
KGN M4frbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LlbGlEPTB;Mj6xOUBvVQ>? Mln5V2FPT0WU
ES4 NVfnPIlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnO[XJrUUN3ME2yMlE3KG6P M4TNZnNCVkeHUh?=
SJSA-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnHTWM2OD1{LkKxJI5O MVXTRW5ITVJ?
KMOE-2 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPxeoRKSzVyPUKuNlMhdk1? M4XHcnNCVkeHUh?=
NB5 Ml7BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnziTWM2OD1{LkK3JI5O NWCwbFFzW0GQR1XS
BC-1 M3qx[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jlTmlEPTB;Mj6zNUBvVQ>? MXzTRW5ITVJ?
NB10 NGH3dZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXabnVKSzVyPUKuN|Ihdk1? MWPTRW5ITVJ?
RPMI-8226 NITQfJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3WUo9KSzVyPUKuN|Uhdk1? MkL0V2FPT0WU
SCC-3 NW\NZXlnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXr3NW5rUUN3ME2yMlM4KG6P MlzRV2FPT0WU
ARH-77 NX7qZ3Z1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTJwM{igcm0> MlfrV2FPT0WU
NCI-H748 MmXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXK1WZo6UUN3ME2yMlM6KG6P NF;mW2ZUSU6JRWK=
KU812 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHOyZ2hKSzVyPUKuOFIhdk1? MXjTRW5ITVJ?
NCI-H64 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnqfY4yUUN3ME2yMlQ1KG6P MXnTRW5ITVJ?
NB69 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzGVYZ1UUN3ME2yMlQ3KG6P MoLkV2FPT0WU
KNS-81-FD NE[5fVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHK0XXhKSzVyPUKuOFghdk1? Mn:2V2FPT0WU
LB1047-RCC M1TSVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTJwNUegcm0> NWXZZ5o{W0GQR1XS
EB-3 NWTLfVBKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVm5PXI6UUN3ME2yMlY3KG6P NGTCfGZUSU6JRWK=
Mo-T MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrzRXhnUUN3ME2yMlc1KG6P MXfTRW5ITVJ?
EW-16 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITFVIVKSzVyPUKuO|Uhdk1? NFO0[|VUSU6JRWK=
CTV-1 M2rQbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXoTWM2OD1{Lkigcm0> MkGyV2FPT0WU
ETK-1 NX;VV4tPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPl[YpbUUN3ME2yMlg1KG6P MmfMV2FPT0WU
C2BBe1 Mo\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTJwOEmgcm0> NUnNTplYW0GQR1XS
MOLT-16 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTJwOEmgcm0> NGTUUXFUSU6JRWK=
SW954 M1XVRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInnNoFKSzVyPUKuPUBvVQ>? NUDOVm1NW0GQR1XS
HT NVi3WlViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXToXnBHUUN3ME2zMlAzKG6P M1nVZ3NCVkeHUh?=
KARPAS-299 NVuwW4l6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfWVYlKSzVyPUOuNFYhdk1? NIL5dopUSU6JRWK=
MONO-MAC-6 MlK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXW5foR2UUN3ME2zMlEhdk1? NGDXR21USU6JRWK=
CGTH-W-1 M3KwVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvoZ|BKSzVyPUOuNUBvVQ>? NUDDVHd2W0GQR1XS
SK-PN-DW M362emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LKXWlEPTB;Mz6xOEBvVQ>? M1;JO3NCVkeHUh?=
CW-2 MkDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYr4XIIzUUN3ME2zMlIyKG6P MkHiV2FPT0WU
SK-N-DZ NHrUelZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVn3eYFpUUN3ME2zMlI3KG6P MlvqV2FPT0WU
NEC8 Mn:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPNTWM2OD1|LkO1JI5O MX7TRW5ITVJ?
LB996-RCC NXvLfYk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXUTWM2OD1|LkSgcm0> MVnTRW5ITVJ?
DB MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPkTWM2OD1|LkSxJI5O NGL6Z|JUSU6JRWK=
TE-15 MnS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXyTWM2OD1|LkSzJI5O MmHxV2FPT0WU
COR-L88 MmT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTIO4lTUUN3ME2zMlQ4KG6P M2PaS3NCVkeHUh?=
LAMA-84 M4L2Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVSxdpBsUUN3ME2zMlQ6KG6P MkjHV2FPT0WU
MEG-01 M{K5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLIcmo4UUN3ME2zMlQ6KG6P MVPTRW5ITVJ?
LOXIMVI NYe3cmE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV72WWY1UUN3ME2zMlUhdk1? MoO1V2FPT0WU
RPMI-8402 NIrqTXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTNwNTDuUS=> MXvTRW5ITVJ?
KARPAS-45 NVn3V2QzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInhVm1KSzVyPUOuOVQhdk1? NVf0UmROW0GQR1XS
HCC1187 M1zyO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTNwNUSgcm0> MWrTRW5ITVJ?
MZ1-PC NU[3W2dzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTNwNUSgcm0> NVrVcHNXW0GQR1XS
no-11 NHnHTJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTNwNUWgcm0> MoHnV2FPT0WU
EVSA-T NXznPVl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7wVmZKSzVyPUOuOkBvVQ>? NH24bYpUSU6JRWK=
DJM-1 M3zyPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mne0TWM2OD1|Lk[zJI5O MXTTRW5ITVJ?
COLO-684 NWjaZ2ZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTNwNk[gcm0> MlXXV2FPT0WU
NMC-G1 NF7KW3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfodXU1UUN3ME2zMlY5KG6P MV\TRW5ITVJ?
LC-1F M3PYcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3j4TWlEPTB;Mz63OEBvVQ>? MV;TRW5ITVJ?
RL95-2 NVvpSFBUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTNwN{mgcm0> NWLvOmE4W0GQR1XS
COLO-320-HSR NFThSJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTvTWM2OD1|LkmyJI5O M1H4NnNCVkeHUh?=
RCC10RGB M4njSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvzUnBKSzVyPUOuPVMhdk1? Mme4V2FPT0WU
HD-MY-Z MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfI[4xKSzVyPUOuPVMhdk1? M17VOnNCVkeHUh?=
NCI-H2141 NH\QWmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnTO|lpUUN3ME20MlA2KG6P NWXFeow{W0GQR1XS
K-562 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYCyNmpRUUN3ME20MlEzKG6P NGn2WnJUSU6JRWK=
NCI-H1648 NVPlNHpHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zZTmlEPTB;ND6xN{BvVQ>? MVTTRW5ITVJ?
OMC-1 M4[1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn[wTWM2OD12LkG4JI5O MWHTRW5ITVJ?
LB647-SCLC MmWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnm2TWM2OD12LkKyJI5O M{i3dHNCVkeHUh?=
TE-12 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH:xOnBKSzVyPUSuNlUhdk1? M4P1VHNCVkeHUh?=
NOMO-1 NEjoTFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4SwcWlEPTB;ND6zN{BvVQ>? NIWzcmVUSU6JRWK=
Raji NF75VlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XCb2lEPTB;ND60OkBvVQ>? MWDTRW5ITVJ?
NALM-6 NWTTSJgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXL[|hKSzVyPUSuOFkhdk1? NUfwTWo2W0GQR1XS
HL-60 NVzUO3hvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPXTWM2OD12Lk[3JI5O MYnTRW5ITVJ?
IST-SL1 NI\WUllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{O1fmlEPTB;ND62PEBvVQ>? M3vHd3NCVkeHUh?=
MHH-PREB-1 NFnZdohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fVZmlEPTB;ND64OkBvVQ>? NVXNSHllW0GQR1XS
MHH-NB-11 NY[zSFdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fzXGlEPTB;ND65NUBvVQ>? NYqzcXpEW0GQR1XS
JiyoyeP-2003 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfRZlc5UUN3ME21JI5O MUfTRW5ITVJ?
SBC-1 NWO2TmIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPEUWRKSzVyPUWuNFEhdk1? MmjzV2FPT0WU
CHP-126 NV\Cb3hoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlK0TWM2OD13LkC2JI5O M2\hRXNCVkeHUh?=
LU-139 NGjOcI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETBS5JKSzVyPUWuNVMhdk1? MUnTRW5ITVJ?
NCI-SNU-5 NEDteZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljZTWM2OD13LkG3JI5O M1LyTXNCVkeHUh?=
SW962 NXvXVnpvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3r2VmlEPTB;NT6yNUBvVQ>? MmjMV2FPT0WU
EW-1 MlPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3KNopKSzVyPUWuN|Ehdk1? M{DQcXNCVkeHUh?=
NCI-H1417 NUfiPHJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4ntNGlEPTB;NT61NUBvVQ>? NIq5RmZUSU6JRWK=
LU-65 NYLMXnVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTVwOESgcm0> NWTO[FdQW0GQR1XS
D-502MG MlzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnJTWM2OD14LkO3JI5O NUnC[VlOW0GQR1XS
BC-3 MmHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3mW2RKSzVyPU[uOlEhdk1? M1;oRXNCVkeHUh?=
GDM-1 M3q3T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTZwN{egcm0> MoTFV2FPT0WU
NCI-H2196 M1\ibGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7UTWM2OD14Lkigcm0> NIDRVGpUSU6JRWK=
NB1 M4SxfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfZPWdKSzVyPU[uPFghdk1? NGT5VnlUSU6JRWK=
NCI-H345 NXiyNWdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTdwMjDuUS=> MWjTRW5ITVJ?
SU-DHL-1 NEewO|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;oV4xKSzVyPUeuNlQhdk1? NVnWcFdXW0GQR1XS
JVM-2 NV;J[2tuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTdwMkigcm0> MUHTRW5ITVJ?
LU-134-A MlTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvxWHVKSzVyPUeuN|khdk1? M3qzcXNCVkeHUh?=
NCI-H1694 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zHUWlEPTB;Nz61PEBvVQ>? MX3TRW5ITVJ?
NCI-SNU-16 M1fDVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{iweWlEPTB;Nz62OUBvVQ>? MkjjV2FPT0WU
L-363 MnjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXyTWM2OD15Lkegcm0> NHvv[IdUSU6JRWK=
KG-1 NIfkWFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPMTWM2OD15Lkm0JI5O MWfTRW5ITVJ?
MN-60 NVLleGVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonOTWM2OD16LkG0JI5O NFXWc3VUSU6JRWK=
NB6 MlPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\h[IxRUUN3ME24MlQ5KG6P M2LacHNCVkeHUh?=
MLMA NWPYbY1pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjteoV4UUN3ME24Mlg2KG6P MYDTRW5ITVJ?
ATN-1 NH;mfHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDzUGZKSzVyPUiuPFkhdk1? MV7TRW5ITVJ?
SK-NEP-1 NYPtOYNbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrmT4Y6UUN3ME25MlAyKG6P M1e5W3NCVkeHUh?=
DMS-114 NFXOZXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTqcW5zUUN3ME25MlYzKG6P MmXQV2FPT0WU
CTB-1 MlvBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTlwNkegcm0> NULTOYcyW0GQR1XS
NCI-H2081 MnznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nhVGlEPTB;MUCuNFkhdk1? MmfBV2FPT0WU
ES5 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DDZ2lEPTB;MUCuN|ghdk1? NHjhPHhUSU6JRWK=
HCC1599 M{fpdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTFzLkmxJI5O MmLGV2FPT0WU
NCI-H23 M2\COWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfaTWM2OD1zMj6xNkBvVQ>? NU\DbpFHW0GQR1XS
NCI-H1581 M1jRdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmK2TWM2OD1zMj6yPEBvVQ>? MVLTRW5ITVJ?
JVM-3 NE\EZXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLRXGdKSzVyPUGyMlk6KG6P MUHTRW5ITVJ?
NCI-SNU-1 NHSyfWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DU[mlEPTB;MUOuNVkhdk1? NHLIc5BUSU6JRWK=
NB7 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDIdVVKSzVyPUG1MlkzKG6P NXfZfJZWW0GQR1XS
JAR MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTF4LkGzJI5O NXvD[pJvW0GQR1XS
TGW MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELsSolKSzVyPUG2MlQ5KG6P MkTjV2FPT0WU
U-87-MG MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTIVoRiUUN3ME2xOk44PiCwTR?= NVW5T5BRW0GQR1XS
NCI-H1436 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\x[mRKSzVyPUG3MlAyKG6P MVnTRW5ITVJ?
GOTO MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIH2XZpKSzVyPUG3MlA3KG6P MnXhV2FPT0WU
COLO-800 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTF5Lk[0JI5O M{n6bXNCVkeHUh?=
MFM-223 M33wR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTF5LkmxJI5O MmLyV2FPT0WU
EW-18 MoTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGG2U|hKSzVyPUG3Mlk3KG6P NV\xbGNwW0GQR1XS
NB14 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfndpRxUUN3ME2xO{46QCCwTR?= MorCV2FPT0WU
EB2 NE\acmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV:yfGU2UUN3ME2xPE4xQCCwTR?= MW\TRW5ITVJ?
EoL-1- NHy2VopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2W0dmlEPTB;MUiuN|Ehdk1? M3TsPXNCVkeHUh?=
NCCIT MkjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTF6LkO2JI5O MWTTRW5ITVJ?
DG-75 NWn2W2VzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTF6Lk[xJI5O Mo\KV2FPT0WU
HCC2218 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTF7LkWgcm0> NUm1c3RQW0GQR1XS
TE-6 NEXwUZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfXVXhxUUN3ME2yNE4xQCCwTR?= MnXQV2FPT0WU
SF539 M1K3O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTJyLk[3JI5O M1fzenNCVkeHUh?=
NCI-H446 M3K1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\mXGlEPTB;MkGuNVghdk1? NFvWeoFUSU6JRWK=
IST-MES1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXwfohMUUN3ME2yNk44PyCwTR?= NGjXWIVUSU6JRWK=
NCI-H82 NGqyR5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjQZ4c5UUN3ME2yN{4xOiCwTR?= MnvpV2FPT0WU
HCC2157 M4KzSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrtTWM2OD1{Mz6xN{BvVQ>? Ml2yV2FPT0WU
EW-12 Mk\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrzTWM2OD1{Mz6xO{BvVQ>? MYPTRW5ITVJ?
SIMA Ml3nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLXTWM2OD1{Mz6zPEBvVQ>? MojCV2FPT0WU
DOHH-2 NYTQeoVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzTeI1SUUN3ME2yN{41PSCwTR?= Mn24V2FPT0WU
IM-9 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTJ|LkW0JI5O M33pPHNCVkeHUh?=
EC-GI-10 MorkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;jTWM2OD1{ND6yN{BvVQ>? Mk\OV2FPT0WU
HDLM-2 NI\LW3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\pV|h6UUN3ME2yOE42PCCwTR?= MXPTRW5ITVJ?
LS-1034 M1rYUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3i4U2lEPTB;MkWuO|Uhdk1? NFj2bXJUSU6JRWK=
REH MnrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUH5UI5VUUN3ME2yOk41OSCwTR?= NWPtRZl[W0GQR1XS
LU-165 M3H2SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfmVIhKSzVyPUK2MlczKG6P M1LnUnNCVkeHUh?=
NH-12 MoXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTJ5Lk[3JI5O Mn;hV2FPT0WU
WSU-NHL NUHZWlBKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTJ6LkO5JI5O MYTTRW5ITVJ?
ECC4 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7ISnVZUUN3ME2yPE44QSCwTR?= Mn\4V2FPT0WU
OCI-AML2 NH6xe3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTJ7Lk[5JI5O MXLTRW5ITVJ?
EW-3 MorYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MleyTWM2OD1|MD61PUBvVQ>? MnP2V2FPT0WU
NCI-H526 M4r2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XhOWlEPTB;M{KuOVQhdk1? NHflNlJUSU6JRWK=
NCI-H719 NF63[ohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjNZYFNUUN3ME2zOE4{OSCwTR?= MVLTRW5ITVJ?
KARPAS-422 MoHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlznTWM2OD1|NT6wOEBvVQ>? MYfTRW5ITVJ?
SK-MEL-1 Mn30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrOfIN2UUN3ME2zOU4yPyCwTR?= M1q3[3NCVkeHUh?=
ES3 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEKwXJdKSzVyPUO1MlE6KG6P MkXJV2FPT0WU
UACC-812 MnrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTN3LkS0JI5O MWnTRW5ITVJ?
C8166 M{LoOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvId2EyUUN3ME2zOU44KG6P MVvTRW5ITVJ?
MDA-MB-134-VI NY\MV5ZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUW4OYUyUUN3ME2zOU45PyCwTR?= MUPTRW5ITVJ?
D-283MED NV\rcoZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3qwemlEPTB;M{euO|khdk1? M4CwfnNCVkeHUh?=
SHP-77 M3P4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjEe3hKSzVyPUO4MlA{KG6P NXu1bmJUW0GQR1XS
NCI-H2227 NE\WO5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXtTWM2OD12MD60PUBvVQ>? MYnTRW5ITVJ?
SKM-1 M3rkSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{izPGlEPTB;NEKuOlMhdk1? M4PweHNCVkeHUh?=
L-428 NFn5XmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3qwSmlEPTB;NEOuPFYhdk1? M1j4OHNCVkeHUh?=
RPMI-6666 NISzc|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXxTZFKSzVyPUS1Mlg6KG6P NIT5e3dUSU6JRWK=
NCI-H716 NIrhWYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3qTWM2OD12OD64NUBvVQ>? MYTTRW5ITVJ?
DMS-79 Mlv4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnmWYVQUUN3ME21NE44OSCwTR?= M3rNdHNCVkeHUh?=
RS4-11 NIfx[lBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnf4TWM2OD13MD64PEBvVQ>? NHzLWVJUSU6JRWK=
NCI-H720 NFLzS2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPyRm9KSzVyPUWxMlEyKG6P M1qwbHNCVkeHUh?=
MC-CAR MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPRU|FKSzVyPUWxMlUzKG6P MV7TRW5ITVJ?
TALL-1 MkTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTV|LkmxJI5O MYXTRW5ITVJ?
NCI-N87 NGjib3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\ifodKSzVyPUW0MlE5KG6P MWXTRW5ITVJ?
P30-OHK MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTV2Lk[xJI5O NX3iNppKW0GQR1XS
LP-1 M3fTXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DSTGlEPTB;NkGuNlghdk1? NGHjNIdUSU6JRWK=
YT NWDEdpBrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTZzLkigcm0> MUHTRW5ITVJ?
MRK-nu-1 Ml34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;OWmlEPTB;NkGuPFIhdk1? MVPTRW5ITVJ?
BT-474 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrIdnRKSzVyPU[1JI5O NHfTUo5USU6JRWK=
NCI-H322M NY\xW2FHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVu4[IRQUUN3ME22Ok4yOSCwTR?= NIHab|dUSU6JRWK=
NCI-H128 NWrobmVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLDTWM2OD15ND63O{BvVQ>? MXzTRW5ITVJ?
KMS-12-PE M3HabGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHRTWM2OD15Nj6yOEBvVQ>? NVrOVHg2W0GQR1XS
KP-N-YS NWn1TGhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\kSWlEPTB;N{[uO|Qhdk1? MmP6V2FPT0WU
ALL-PO NHH3Z2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;OTWM2OD15Nz62OkBvVQ>? NIK4OW9USU6JRWK=
EW-13 MlrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnld|FJUUN3ME23O{44PiCwTR?= MYnTRW5ITVJ?
EW-11 NVfkUWpHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mly3TWM2OD15OD61NkBvVQ>? MkfQV2FPT0WU
SK-N-FI M2PlVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HQU2lEPTB;OECuNkBvVQ>? MV3TRW5ITVJ?
CAL-148 M2P2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3uPVJKSzVyPUixMlg1KG6P MVrTRW5ITVJ?
RL MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfJelhKSzVyPUi2MlA6KG6P NXrpXJJXW0GQR1XS
AM-38 NFLQRpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrZTWM2OD16OD6wPEBvVQ>? NXLLNYlXW0GQR1XS
RH-1 NEnKSlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7BZ4pzUUN3ME25PU45PSCwTR?= NGm2NmtUSU6JRWK=
NCI-H1770 Mnu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknuTWM2OD1zMEKuOFkhdk1? MnG0V2FPT0WU
SIG-M5 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\iTWM2OD1zMEWuNFYhdk1? NGficmtUSU6JRWK=
GR-ST NVrSepdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTFzMz6zOEBvVQ>? NGLrTWNUSU6JRWK=
ST486 NVTP[4ZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1yyRWlEPTB;MUG0MlA3KG6P MmPiV2FPT0WU
NCI-H1650 M37LUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUO0TGt1UUN3ME2xNVUvOjlibl2= NVf3WYNqW0GQR1XS
MHH-CALL-2 NVXPO4U2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTFzNT63JI5O MmrKV2FPT0WU
BV-173 M1jIS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1KzbmlEPTB;MUKyMlcyKG6P M1XZVnNCVkeHUh?=
MC116 NVzEZpA3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrRTJlKSzVyPUG0PE45PSCwTR?= MVPTRW5ITVJ?
NCI-H524 NXzpeW5xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\Hb2lEPTB;MUW5MlEhdk1? Mo[5V2FPT0WU
SCLC-21H NHjKc41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXuXplKSzVyPUG1PU41OSCwTR?= NV[we2J5W0GQR1XS
NCI-H1304 M3vnW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1qy[WlEPTB;MU[5MlIyKG6P M1vuSHNCVkeHUh?=
NCI-H510A MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTF6NT6zO{BvVQ>? MWjTRW5ITVJ?
NCI-H209 NUHSXph{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTF7Nj61NkBvVQ>? M4SxbHNCVkeHUh?=
KM-H2 M2e3bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDSVlBYUUN3ME2xPVcvODVibl2= M4qyOHNCVkeHUh?=
NCI-H1395 NH3lbGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHXWJZ2UUN3ME2yNVAvOTNibl2= MX3TRW5ITVJ?
NCI-H1155 NXrxWYt6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXrTWM2OD1{M{CuN|Ihdk1? Ml\iV2FPT0WU
COR-L279 NI\ZVI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTJ3Mj6xO{BvVQ>? NV7QVmcxW0GQR1XS
NCI-H1299 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTJ4MT63NUBvVQ>? MXjTRW5ITVJ?
EW-22 Mn7GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHxTWM2OD1{NkOuO|Uhdk1? Mlr0V2FPT0WU
SK-MEL-2 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjqTGt5UUN3ME2yPFEvQSCwTR?= NXrBfpYyW0GQR1XS
KASUMI-1 MlHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVm5fGZyUUN3ME2yPFMvODVibl2= NV\GWFl3W0GQR1XS
NCI-H187 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXnTWM2OD1{OEeuNFghdk1? NH3nd|FUSU6JRWK=
NCI-H2171 MnfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\DcmlEPTB;Mki4MlkzKG6P MXfTRW5ITVJ?
LNCaP-Clone-FGC MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mki5TWM2OD1{OUWuNlYhdk1? MYjTRW5ITVJ?
NCI-H1522 Mki5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYi5PYN3UUN3ME2zNFcvODVibl2= MXnTRW5ITVJ?
SCH NFnBN|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\hXWlEPTB;M{KyMlIzKG6P Mkn5V2FPT0WU
THP-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETkNlBKSzVyPUOyNk43KG6P M1PZW3NCVkeHUh?=
SNU-C1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTN4Mj6wPUBvVQ>? NWHyN5luW0GQR1XS
CA46 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHz2ZZFKSzVyPUO3N{43OyCwTR?= M2HDPHNCVkeHUh?=
NCI-H1963 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzBdIhKSzVyPUO4Ok4yQSCwTR?= M4jTO3NCVkeHUh?=
DEL MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TPbmlEPTB;M{mxMlI4KG6P Mn\UV2FPT0WU
TUR NHn6NotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3q2bGlEPTB;M{m2MlYyKG6P NXvsSHZlW0GQR1XS
NCI-H226 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEG2eYtKSzVyPUSwN{4zOyCwTR?= NWTUc2VyW0GQR1XS
COLO-668 NH3aZ|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTRyMz61O{BvVQ>? NFLtSllUSU6JRWK=
CPC-N Ml3xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkW0TWM2OD12MEOuO|chdk1? Mkn5V2FPT0WU
NCI-H889 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWWzVndTUUN3ME20OlEvQTJibl2= MX7TRW5ITVJ?
J-RT3-T3-5 Mn64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnj2TWM2OD13M{KuOVchdk1? NFXnTnpUSU6JRWK=
MSTO-211H MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\DbY02UUN3ME21O|QvOjZibl2= M2n5VHNCVkeHUh?=
SCC-15 NVTpfGlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkH5TWM2OD14NkeuOFchdk1? M2LVbnNCVkeHUh?=
SUP-T1 MkXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTZ6Nj6wOEBvVQ>? M3;EcHNCVkeHUh?=
DMS-153 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnSfW5QUUN3ME23OFYvQDNibl2= MnXtV2FPT0WU
MS-1 MljwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XS[GlEPTB;N{W5MlQzKG6P M1TvZ3NCVkeHUh?=
TC-YIK NGq1PZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTOZmY{UUN3ME23PFEvODFibl2= MWXTRW5ITVJ?
RPMI-8866 M3;PZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfzZnJCUUN3ME2xNFA3NjJ6IN88US=> M{fQeXNCVkeHUh?=
KY821 NYPhbIxZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmi3TWM2OD1zMEO2MlA1KM7:TR?= NFTSe29USU6JRWK=
P31-FUJ MnPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTFzMUKuO|Uh|ryP MUfTRW5ITVJ?
COLO-824 NGK3RVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfne|ZKSzVyPUGyOlEvPzhizszN MmTuV2FPT0WU
U-698-M NUn3UIFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4D2RmlEPTB;MkK2Nk4yPSEQvF2= NIrqboZUSU6JRWK=
TE-441-T NVK3NHVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXnTWM2OD1{NUKxMlch|ryP MWHTRW5ITVJ?
IMR-5 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\0WmlEPTB;M{SwPU43OiEQvF2= MX7TRW5ITVJ?
NCI-H1838 M32zT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zYcWlEPTB;NEG4Ok4{OiEQvF2= MlriV2FPT0WU

... Click to View More Cell Line Experimental Data

体内研究 Bortezomib单一用药的抗癌作用已在多发性骨髓瘤的异种移植模型,成人白血病,肺癌,乳腺癌,前列腺癌,胰腺癌,头颈癌,和结肠癌,以及在黑色素瘤中得到证实。[2]在Lewis肺癌模型中,口服bortezomib (1.0 mg/ kg,每天),服用18天引起肿瘤生长延迟,并减少转移数量。Bortezomib单一用药, 高达5 mg/kg剂量时显著降低乳腺癌细胞的存活率。在前列腺癌小鼠异种移植模型中,Bortezomib (1.0 mg/kg,每周一次)用药4周减少60%肿瘤生长。1.0 mg/kg Bortezomib给药4周导致胰腺癌小鼠异种移植物生长减少72%或84%,并导致肿瘤细胞凋亡增加。1.0 mg/kg Bortezomib显著抑制人浆细胞瘤异种移植物生长,增加肿瘤细胞凋亡和总存活率,并减少肿瘤血管生成。[3]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[4]

+ 展开

动力学法:

在典型的动力学试验中,2.00 mL试验缓冲液(20 mM HEPES,0.5 mM EDTA,0.035% SDS,pH 7.8) 和 Suc-Leu-Leu-Val-Tyr-AMC溶于DMSO,加入3 mL荧光比色皿中,并将比色皿放置于荧光分光光度计的夹套细胞皿座。反应温度通过循环水浴维持在37℃。反应溶液达到热平衡后(5 分钟),1 μL−10 μL储存酶溶液加入培养皿。伴随AMC 从多肽AMC底物裂解的反应进程通过440 nm (λex= 380 nm)下荧光发射的增加监测。
细胞实验:

[5]

+ 展开
  • Cell lines: 人多发性骨髓瘤细胞系U266
  • Concentrations: ~10 μM
  • Incubation Time: 2天
  • Method:

    通过测定细胞吸收 MTT染料的情况而测定 Bortezomib对 MM和 BMSC 生长的抑制情况。每孔使用10 μL 5 mg/mL MTT对培养48小时的细胞进行脉冲处理,至少处理4小时, 随后加入100 μL 含0.04 N HCl的异丙醇 。使用分光光度计在 570 nm处测定吸光值。


    (Only for Reference)
动物实验:

[3]

+ 展开
  • Animal Models: 人浆细胞瘤异种移植物RPMI 8226
  • Formulation: 生理盐水
  • Dosages: 1mg/kg
  • Administration: i.v.,一周两次,使用4周,然后一周一次
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 76 mg/mL (197.79 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+30% PEG 300+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 384.24
化学式

C19H25BN4O4

CAS号 179324-69-7
稳定性 powder
in solvent
别名 LDP-341, MLM341

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03136146 Recruiting Hematopoietic/Lymphoid Cancer|Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma|Burkitt Leukemia/Lymphoma M.D. Anderson Cancer Center August 9 2017 Phase 2
NCT02951819 Active not recruiting Multiple Myeloma Janssen Scientific Affairs LLC November 9 2016 Phase 2
NCT01453101 Active not recruiting Multiple Myeloma Hackensack Meridian Health June 9 2010 Phase 2
NCT01449344 Active not recruiting Mantle Cell Lymphoma Prof. Dr. M. Dreyling (co-chairman)|Klinikum der Universitaet Muenchen Grosshadern|ClinAssess GmbH|GELARC Service de Pharmacovigilance Pierre Benite|European Mantle Cell Lymphoma Network May 9 2009 Phase 3
NCT00703664 Completed Recurrent Mantle Cell Lymphoma|Recurrent Non-Hodgkin Lymphoma National Cancer Institute (NCI) July 9 2008 Phase 2
NCT01965977 Recruiting Diffuse Large B Cell Lymphoma Samsung Medical Center|Janssen LP April 8 2015 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    On your website, it is mentioned that Bortezomib should be prepared at a concentration of 5 mg/ml in 2% DMSO/30% PEG300/ddH2O for in vivo use. But on the product sheet we received with the compound, it is mentioned: 5mg/ml in 0.5% methylcellulose, 0.2% tween 80. So which is the correct preparation buffer?

  • 回答:

    S1013 Bortezomib in 2% DMSO+30% PEG 300+ddH2O at 5 mg/ml is a clear solution, and it in 0.5% methylcellulose+0.2% Tween 80 is a suspension. Please choose the suitable vehicle according to your administration route. When you prepare the clear solution, please dissolve Bortezomib in DMSO first, make sure it dissolves well, warm it up to 45 degree and/or sonicate if necessary, then add PEG, mix well, and finally add water.

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

相关Proteasome产品

Tags: 购买Bortezomib (PS-341) | Bortezomib (PS-341)供应商 | 采购Bortezomib (PS-341) | Bortezomib (PS-341)价格 | Bortezomib (PS-341)生产 | 订购Bortezomib (PS-341) | Bortezomib (PS-341)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID